Clinical research
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 18, 2020.
Exicure announced positive results from its Phase Ib trial evaluating cavrotolimod, its SNA-enabled TLR9 agonist, that is being developed for the treatment of solid tumors, in combination with pembrolizumab.
Eli Lilly and Company announced interim proof-of-concept data from its BLAZE-1 Phase II clinical trial of LY-COV555, its neutralizing antibody therapy for COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 16, 2020.
Shares of Marinus Pharmaceuticals soared more than 60% in after-hours trading Monday following the company’s announcement that its experimental epilepsy treatment ganaxolone hit the mark in a Phase III study.
AstraZeneca resumed its vaccine testing in the United Kingdom following confirmation from the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 14, 2020.
Eli Lilly and Company announced today that it has seen positive results from CENTURION, its Phase III study looking into Reyvow (lasmiditan) for migraine attacks.
It was a busy week for clinical trial updates. Here’s a look.
Based on the positive results of Trikafta, the company plans to submit sNDA to the FDA in the fourth quarter and other regulatory agencies around the world afterward.
PRESS RELEASES